{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:30:12Z","timestamp":1783121412415,"version":"3.54.6"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-025-00562-1","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T09:56:02Z","timestamp":1752832562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Drug repositioning: examining antipsychotic drugs and their anticancer effects"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0929-5236","authenticated-orcid":false,"given":"Aysen","family":"Sagnak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-7908","authenticated-orcid":false,"given":"Ferda","family":"Ari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"562_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.canlet.2018.01.058","volume":"419","author":"J Huang","year":"2018","unstructured":"Huang J, Zhao D, Liu Z, Liu F. Repurposing psychiatric drugs as anti-cancer agents. Cancer Lett. 2018;419:257\u201365. https:\/\/doi.org\/10.1016\/j.canlet.2018.01.058.","journal-title":"Cancer Lett"},{"issue":"1","key":"562_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"562_CR3","doi-asserted-by":"publisher","first-page":"e0235676","DOI":"10.1371\/journal.pone.0235676","volume":"15","author":"A Badran","year":"2020","unstructured":"Badran A, Tul-Wahab A, Zafar H, Mohammad N, Imad R, Ashfaq Khan M, Baydoun E, Choudhary MI. Antipsychotics drug Aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro. PLoS ONE. 2020;15(8):e0235676. https:\/\/doi.org\/10.1371\/journal.pone.0235676.","journal-title":"PLoS ONE"},{"issue":"2","key":"562_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4306\/pi.2011.8.2.77","volume":"8","author":"A Preti","year":"2011","unstructured":"Preti A, Wilson DR. Schizophrenia, cancer and obstetric complications in an evolutionary perspective-an empirically based hypothesis. Psychiatry Invest. 2011;8(2):77\u201388. https:\/\/doi.org\/10.4306\/pi.2011.8.2.77.","journal-title":"Psychiatry Invest"},{"issue":"12","key":"562_CR5","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/cncr.21574","volume":"104","author":"Y Barak","year":"2005","unstructured":"Barak Y, Achiron A, Mandel M, Mirecki I, Aizenberg D. Reduced cancer incidence among patients with schizophrenia. Cancer. 2005;104(12):2817\u201321. https:\/\/doi.org\/10.1002\/cncr.21574.","journal-title":"Cancer"},{"issue":"2\u20133","key":"562_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s0920-9964(01)00308-5","volume":"57","author":"M Cohen","year":"2002","unstructured":"Cohen M, Dembling B, Schorling J. The association between schizophrenia and cancer: a population-based mortality study. Schizophr Res. 2002;57(2\u20133):139\u201346. https:\/\/doi.org\/10.1016\/s0920-9964(01)00308-5.","journal-title":"Schizophr Res"},{"key":"562_CR7","doi-asserted-by":"publisher","first-page":"102233","DOI":"10.1016\/j.canep.2022.102233","volume":"80","author":"JC Wootten","year":"2022","unstructured":"Wootten JC, Wiener JC, Blanchette PS, Anderson KK. Cancer incidence and stage at diagnosis among people with psychotic disorders: systematic review and meta-analysis. Cancer Epidemiol. 2022;80:102233. https:\/\/doi.org\/10.1016\/j.canep.2022.102233.","journal-title":"Cancer Epidemiol"},{"issue":"12","key":"562_CR8","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/biomedicines9121785","volume":"9","author":"N Vlachos","year":"2021","unstructured":"Vlachos N, Lampros M, Voulgaris S, Alexiou GA. Repurposing antipsychotics for Cancer treatment. Biomedicines. 2021;9(12):1785. https:\/\/doi.org\/10.3390\/biomedicines9121785.","journal-title":"Biomedicines"},{"issue":"4","key":"562_CR9","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.14318","volume":"111","author":"T Masuda","year":"2020","unstructured":"Masuda T, Tsuruda Y, Matsumoto Y, Uchida H, Nakayama KI, Mimori K. Drug repositioning in cancer: the current situation in Japan. Cancer Sci. 2020;111(4):1039\u201346. https:\/\/doi.org\/10.1111\/cas.14318.","journal-title":"Cancer Sci"},{"issue":"4","key":"562_CR10","first-page":"495","volume":"3","author":"TA Ban","year":"2007","unstructured":"Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2007;3(4):495\u2013500.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"562_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.canlet.2021.12.014","volume":"527","author":"F You","year":"2022","unstructured":"You F, Zhang C, Liu X, Ji D, Zhang T, Yu R, Gao S. Drug repositioning: using psychotropic drugs for the treatment of glioma. Cancer Lett. 2022;527:140\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2021.12.014.","journal-title":"Cancer Lett"},{"key":"562_CR12","doi-asserted-by":"publisher","first-page":"635472","DOI":"10.3389\/fonc.2021.635472","volume":"11","author":"S Matteoni","year":"2021","unstructured":"Matteoni S, Matarrese P, Ascione B, Buccarelli M, Ricci-Vitiani L, Pallini R, Villani V, Pace A, Paggi MG, Abbruzzese C. Anticancer properties of the antipsychotic drug chlorpromazine and its synergism with Temozolomide in restraining human glioblastoma proliferation in vitro. Front Oncol. 2021;11:635472. https:\/\/doi.org\/10.3389\/fonc.2021.635472.","journal-title":"Front Oncol"},{"key":"562_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1196\/annals.1414.041","volume":"1138","author":"JH Choi","year":"2008","unstructured":"Choi JH, Yang YR, Lee SK, Kim SH, Kim YH, Cha JY, Oh SW, Ha JR, Ryu SH, Suh PG. Potential Inhibition of PDK1\/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival. Ann N Y Acad Sci. 2008;1138:393\u2013403. https:\/\/doi.org\/10.1196\/annals.1414.041.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"562_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3322\/caac.21285","volume":"65","author":"RD Mehta","year":"2015","unstructured":"Mehta RD, Roth AJ. Psychiatric considerations in the oncology setting. Cancer J Clin. 2015;65(4):300\u201314. https:\/\/doi.org\/10.3322\/caac.21285.","journal-title":"Cancer J Clin"},{"issue":"3","key":"562_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00280-021-04386-z","volume":"89","author":"F Xu","year":"2022","unstructured":"Xu F, Xi H, Liao M, Zhang Y, Ma H, Wu M, Xue Q, Sun H, Zhang Y, Xia Y. Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2\/M cell cycle arrest, apoptosis, and autophagy. Cancer Chemother Pharmacol. 2022;89(3):331\u201346. https:\/\/doi.org\/10.1007\/s00280-021-04386-z.","journal-title":"Cancer Chemother Pharmacol"},{"key":"562_CR16","doi-asserted-by":"publisher","first-page":"665832","DOI":"10.3389\/fonc.2021.665832","volume":"11","author":"Y Cui","year":"2021","unstructured":"Cui Y, Wu H, Yang L, Huang T, Li J, Gong X, Li L, Sun X, Mao F, Wang Y. Chlorpromazine sensitizes Progestin-Resistant endometrial Cancer cells to MPA by upregulating PRB. Front Oncol. 2021;11:665832. https:\/\/doi.org\/10.3389\/fonc.2021.665832.","journal-title":"Front Oncol"},{"key":"562_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.canlet.2018.06.034","volume":"433","author":"MM Chan","year":"2018","unstructured":"Chan MM, Chen R, Fong D. Targeting cancer stem cells with dietary phytochemical- repositioned drug combinations. Cancer Lett. 2018;433:53\u201364. https:\/\/doi.org\/10.1016\/j.canlet.2018.06.034.","journal-title":"Cancer Lett"},{"issue":"5","key":"562_CR18","doi-asserted-by":"publisher","first-page":"e1753","DOI":"10.1038\/cddis.2015.77","volume":"6","author":"HW Cheng","year":"2015","unstructured":"Cheng HW, Liang YH, Kuo YL, Chuu CP, Lin CY, Lee MH, Wu AT, Yeh CT, Chen EI, Whang-Peng J, Su CL, Huang CY. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data. Cell Death Dis. 2015;6(5):e1753. https:\/\/doi.org\/10.1038\/cddis.2015.77.","journal-title":"Cell Death Dis"},{"issue":"3","key":"562_CR19","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3892\/ol.2017.5651","volume":"13","author":"J Shen","year":"2017","unstructured":"Shen J, Ma B, Zhang X, Sun X, Han J, Wang Y, Chu L, Xu H, Yang Y. Thioridazine has potent antitumor effects on lung cancer stem-like cells. Oncol Lett. 2017;13(3):1563\u20138. https:\/\/doi.org\/10.3892\/ol.2017.5651.","journal-title":"Oncol Lett"},{"issue":"9","key":"562_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10495-012-0717-2","volume":"17","author":"S Kang","year":"2012","unstructured":"Kang S, Dong SM, Kim BR, Park MS, Trink B, Byun HJ, Rho SB. Thioridazine induces apoptosis by targeting the PI3K\/Akt\/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. 2012;17(9):989\u201397. https:\/\/doi.org\/10.1007\/s10495-012-0717-2.","journal-title":"Apoptosis"},{"issue":"6","key":"562_CR21","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1172\/JCI35931","volume":"118","author":"PA Arguello","year":"2008","unstructured":"Arguello PA, Gogos JA. A signaling pathway AKTing up in schizophrenia. J Clin Investig. 2008;118(6):2018\u201321. https:\/\/doi.org\/10.1172\/JCI35931.","journal-title":"J Clin Investig"},{"issue":"1","key":"562_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ygyno.2010.10.003","volume":"120","author":"SB Rho","year":"2011","unstructured":"Rho SB, Kim BR, Kang S. A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3\u2019-kinase (PI3K)\/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011;120(1):121\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2010.10.003.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"562_CR23","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3892\/or.2014.3068","volume":"31","author":"J Mu","year":"2014","unstructured":"Mu J, Xu H, Yang Y, Huang W, Xiao J, Li M, Tan Z, Ding Q, Zhang L, Lu J, Wu X, Liu Y. Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer. Oncol Rep. 2014;31(5):2107\u201314. https:\/\/doi.org\/10.3892\/or.2014.3068.","journal-title":"Oncol Rep"},{"issue":"2","key":"562_CR24","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3892\/or.2016.5313","volume":"37","author":"C Zhang","year":"2017","unstructured":"Zhang C, Gong P, Liu P, Zhou N, Zhou Y, Wang Y. Thioridazine elicits potent antitumor effects in colorectal cancer stem cells. Oncol Rep. 2017;37(2):1168\u201374. https:\/\/doi.org\/10.3892\/or.2016.5313.","journal-title":"Oncol Rep"},{"issue":"24","key":"562_CR25","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1080\/15384101.2020.1850969","volume":"19","author":"Y Song","year":"2020","unstructured":"Song Y, Li L, Chen J, Chen H, Cui B, Feng Y, Zhang P, Zhang Q, Xia Y, Luo M. Thioridazine hydrochloride: an antipsychotic agent that inhibits tumor growth and lung metastasis in triple-negative breast cancer via inducing G0\/G1 arrest and apoptosis. Cell Cycle. 2020;19(24):3521\u201333.","journal-title":"Cell Cycle"},{"issue":"6","key":"562_CR26","first-page":"2767","volume":"8","author":"Q Meng","year":"2016","unstructured":"Meng Q, Sun X, Wang J, Wang Y, Wang L. The important application of thioridazine in the endometrial cancer. Am J Transl Res. 2016;8(6):2767\u201375.","journal-title":"Am J Transl Res"},{"issue":"15","key":"562_CR27","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1182\/bloodadvances.2018015677","volume":"2","author":"L Aslostovar","year":"2018","unstructured":"Aslostovar L, Boyd AL, Almakadi M, Collins TJ, Leong DP, Tirona RG, Kim RB, Julian JA, Xenocostas A, Leber B, Levine MN, Foley R, Bhatia M. A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Adv. 2018;2(15):1935\u201345. https:\/\/doi.org\/10.1182\/bloodadvances.2018015677.","journal-title":"Blood Adv"},{"key":"562_CR28","doi-asserted-by":"publisher","first-page":"CD012122","DOI":"10.1002\/14651858.CD012122.pub2","volume":"4","author":"S Nur","year":"2016","unstructured":"Nur S, Adams CE. Chlorpromazine versus reserpine for schizophrenia. Cochrane Database Syst Rev. 2016;4:CD012122. https:\/\/doi.org\/10.1002\/14651858.CD012122.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"562_CR29","doi-asserted-by":"publisher","first-page":"118730","DOI":"10.1016\/j.lfs.2020.118730","volume":"264","author":"AK Ramu","year":"2021","unstructured":"Ramu AK, Ali D, Alarifi S, Syed Abuthakir MH, Ahmed Abdul BA. Reserpine inhibits DNA repair, cell proliferation, invasion and induces apoptosis in oral carcinogenesis via modulation of TGF-\u03b2 signaling. Life Sci. 2021;264:118730. https:\/\/doi.org\/10.1016\/j.lfs.2020.118730.","journal-title":"Life Sci"},{"issue":"9","key":"562_CR30","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2174\/1871520618666180209152215","volume":"18","author":"MD Ramamoorthy","year":"2018","unstructured":"Ramamoorthy MD, Kumar A, Ayyavu M, Dhiraviam KN. Reserpine induces apoptosis and cell cycle arrest in hormone independent prostate Cancer cells through mitochondrial membrane potential failure. Anti-cancer Agents Med Chem. 2018;18(9):1313\u201322. https:\/\/doi.org\/10.2174\/1871520618666180209152215.","journal-title":"Anti-cancer Agents Med Chem"},{"issue":"3","key":"562_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1208\/s12248-016-9901-6","volume":"18","author":"B Hong","year":"2016","unstructured":"Hong B, Su Z, Zhang C, Yang Y, Guo Y, Li W, Kong AN. Reserpine inhibit the JB6 P\u2009+\u2009Cell transformation through epigenetic reactivation of Nrf2-Mediated Anti-oxidative stress pathway. AAPS J. 2016;18(3):659\u201369. https:\/\/doi.org\/10.1208\/s12248-016-9901-6.","journal-title":"AAPS J"},{"issue":"2","key":"562_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.phymed.2015.01.002","volume":"22","author":"SA Abdelfatah","year":"2015","unstructured":"Abdelfatah SA, Efferth T. Cytotoxicity of the Indole alkaloid reserpine from Rauwolfia serpentina against drug-resistant tumor cells. Phytomedicine: Int J Phytotherapy Phytopharmacology. 2015;22(2):308\u201318. https:\/\/doi.org\/10.1016\/j.phymed.2015.01.002.","journal-title":"Phytomedicine: Int J Phytotherapy Phytopharmacology"},{"issue":"3","key":"562_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/acschemneuro.7b00018","volume":"8","author":"MW Tyler","year":"2017","unstructured":"Tyler MW, Zaldivar-Diez J, Haggarty SJ. Classics in chemical neuroscience: haloperidol. ACS Chem Neurosci. 2017;8(3):444\u201353. https:\/\/doi.org\/10.1021\/acschemneuro.7b00018.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"562_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cellsig.2008.10.005","volume":"21","author":"Z Wei","year":"2009","unstructured":"Wei Z, Qi J, Dai Y, Bowen WD, Mousseau DD. Haloperidol disrupts Akt signalling to reveal a phosphorylation-dependent regulation of pro-apoptotic Bcl-XS function. Cell Signal. 2009;21(1):161\u20138. https:\/\/doi.org\/10.1016\/j.cellsig.2008.10.005.","journal-title":"Cell Signal"},{"issue":"1","key":"562_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pnpbp.2011.08.010","volume":"36","author":"P Gass\u00f3","year":"2012","unstructured":"Gass\u00f3 P, Mas S, Molina O, Bernardo M, Lafuente A, Parellada E. Neurotoxic\/neuroprotective activity of haloperidol, Risperidone and Paliperidone in neuroblastoma cells. Prog Neuro-psychopharmacol Biol Psychiatry. 2012;36(1):71\u20137. https:\/\/doi.org\/10.1016\/j.pnpbp.2011.08.010.","journal-title":"Prog Neuro-psychopharmacol Biol Psychiatry"},{"issue":"1","key":"562_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ijc.24813","volume":"126","author":"ED Wiklund","year":"2010","unstructured":"Wiklund ED, Catts VS, Catts SV, Ng TF, Whitaker NJ, Brown AJ, Lutze-Mann LH. Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target. Int J Cancer. 2010;126(1):28\u201340. https:\/\/doi.org\/10.1002\/ijc.24813.","journal-title":"Int J Cancer"},{"issue":"12","key":"562_CR37","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/biomedicines8120595","volume":"8","author":"F Papadopoulos","year":"2020","unstructured":"Papadopoulos F, Isihou R, Alexiou GA, Tsalios T, Vartholomatos E, Markopoulos GS, Sioka C, Tsekeris P, Kyritsis AP, Galani V. Haloperidol induced cell cycle arrest and apoptosis in glioblastoma cells. Biomedicines. 2020;8(12):595. https:\/\/doi.org\/10.3390\/biomedicines8120595.","journal-title":"Biomedicines"},{"key":"562_CR38","doi-asserted-by":"publisher","first-page":"172402","DOI":"10.1016\/j.ejphar.2019.05.031","volume":"856","author":"N Hendouei","year":"2019","unstructured":"Hendouei N, Saghafi F, Shadfar F, Hosseinimehr SJ. Molecular mechanisms of Anti-Psychotic drugs for improvement of Cancer treatment. Eur J Pharmacol. 2019;856:172402. https:\/\/doi.org\/10.1016\/j.ejphar.2019.05.031.","journal-title":"Eur J Pharmacol"},{"key":"562_CR39","first-page":"1111","volume":"31","author":"R Hilf","year":"1971","unstructured":"Hilf R, Bell C, Goldenberg H, Michel I. Effect of fluphenazine HCl on R3230AC mammary carcinoma and mammary glands of the rat. Cancer Res. 1971;31:1111\u20137.","journal-title":"Cancer Res"},{"issue":"10","key":"562_CR40","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/biom12101360","volume":"12","author":"D Duarte","year":"2022","unstructured":"Duarte D, Vale N. Antipsychotic drug fluphenazine against human Cancer cells. Biomolecules. 2022;12(10):1360. https:\/\/doi.org\/10.3390\/biom12101360.","journal-title":"Biomolecules"},{"key":"562_CR41","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.18632\/oncotarget.26725","volume":"10","author":"MA Goyette","year":"2019","unstructured":"Goyette MA, Cusseddu R, Elkholi I, Abu-Thuraia A, El-Hachem N, Haibe-Kains B, C\u00f4t\u00e9 JF. AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer. Oncotarget. 2019;10:2055\u201367. https:\/\/doi.org\/10.18632\/oncotarget.26725.","journal-title":"Oncotarget"},{"key":"562_CR42","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1038\/cddis.2011.62","volume":"2","author":"D Zong","year":"2011","unstructured":"Zong D, H\u00e5\u00e5g P, Yakymovych I, Lewensohn R, Viktorsson K. Chemosensitization by phenothiazines in human lung cancer cells: impaired resolution of \u03b3H2AX and increased oxidative stress elicit apoptosis associated with lysosomal expansion and intense vacuolation. Cell Death Dis. 2011;2:e181. https:\/\/doi.org\/10.1038\/cddis.2011.62.","journal-title":"Cell Death Dis"},{"key":"562_CR43","unstructured":"Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple. Myeloma\u2014Full text View\u2014ClinicalTrials.Gov. [(accessed on 18 August 2022)]; Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00821301?term=fluphenazine%26;draw=2%26;rank=1."},{"key":"562_CR44","unstructured":"Fluphenazine in Treating Patients with Refractory Advanced Multiple Myeloma\u2014Full. Text View\u2014ClinicalTrials.Gov. [(accessed on 18 August 2022)]; Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00335647?term=fluphenazine%26;draw=2%26;rank=4."},{"issue":"12","key":"562_CR45","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/cancers11121869","volume":"11","author":"C Huang","year":"2019","unstructured":"Huang C, Lan W, Fraunhoffer N, Meilerman A, Iovanna J, Santofimia-Casta\u00f1o P. Dissecting the anticancer mechanism of trifluoperazine on pancreatic ductal adenocarcinoma. Cancers (Basel). 2019;11(12):1869. https:\/\/doi.org\/10.3390\/cancers11121869.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"562_CR46","doi-asserted-by":"publisher","first-page":"15756","DOI":"10.1002\/jcb.28845","volume":"120","author":"K Qian","year":"2019","unstructured":"Qian K, Sun L, Zhou G, Ge H, Meng Y, Li J, Li X, Fang X. Trifluoperazine as an alternative strategy for the Inhibition of tumor growth of colorectal cancer. J Cell Biochem. 2019;120(9):15756\u201365. https:\/\/doi.org\/10.1002\/jcb.28845.","journal-title":"J Cell Biochem"},{"issue":"10","key":"562_CR47","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/s41419-018-1046-3","volume":"9","author":"Z Feng","year":"2018","unstructured":"Feng Z, Xia Y, Gao T, Xu F, Lei Q, Peng C, Yang Y, Xue Q, Hu X, Wang Q, Wang R, Ran Z, Zeng Z, Yang N, Xie Z, Yu L. The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0\/G1 arrest and apoptosis. Cell Death Dis. 2018;9(10):1006. https:\/\/doi.org\/10.1038\/s41419-018-1046-3.","journal-title":"Cell Death Dis"},{"key":"562_CR48","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1089\/dna.2017.3790","volume":"36","author":"J Jiang","year":"2017","unstructured":"Jiang J, Huang Z, Chen X, Luo R, Cai H, Wang H, Zhang H, Sun T, Zhang Y. Trifluoperazine activates FOXO1-Related signals to inhibit tumor growth in hepatocellular carcinoma. DNA Cell Biol. 2017;36:813\u201321.","journal-title":"DNA Cell Biol"},{"key":"562_CR49","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3389\/fphar.2019.01029","volume":"10","author":"Y Xia","year":"2019","unstructured":"Xia Y, Jia C, Xue Q, Jiang J, Xie Y, Wang R, Ran Z, Xu F, Zhang Y, Ye T. Antipsychotic drug trifluoperazine suppresses colorectal Cancer by inducing G0\/G1 arrest and apoptosis. Front Pharmacol. 2019;10:1029.","journal-title":"Front Pharmacol"},{"key":"562_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcancer.2019.10.007","volume":"68","author":"V Shaw","year":"2021","unstructured":"Shaw V, Srivastava S, Srivastava SK. Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy. Sem Cancer Biol. 2021;68:75\u201383. https:\/\/doi.org\/10.1016\/j.semcancer.2019.10.007.","journal-title":"Sem Cancer Biol"},{"issue":"79","key":"562_CR51","doi-asserted-by":"publisher","first-page":"34889","DOI":"10.18632\/oncotarget.26175","volume":"9","author":"el-H Dakir","year":"2018","unstructured":"Dakir el-H, Pickard A, Srivastava K, McCrudden CM, Gross SR, Lloyd S, Zhang SD, Margariti A, Morgan R, Rudland PS, El-Tanani M. The anti-psychotic drug Pimozide is a novel chemotherapeutic for breast cancer. Oncotarget. 2018;9(79):34889\u2013910. https:\/\/doi.org\/10.18632\/oncotarget.26175.","journal-title":"Oncotarget"},{"key":"562_CR52","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3389\/fphar.2019.01517","volume":"10","author":"U Kim","year":"2020","unstructured":"Kim U, Kim CY, Lee JM, Ryu B, Kim J, Shin C, Park JH. Pimozide inhibits the human prostate Cancer cells through the generation of reactive oxygen species. Front Pharmacol. 2020;10:1517. https:\/\/doi.org\/10.3389\/fphar.2019.01517.","journal-title":"Front Pharmacol"},{"key":"562_CR53","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.lfs.2018.08.027","volume":"209","author":"Y Ren","year":"2018","unstructured":"Ren Y, Tao J, Jiang Z, Guo D, Tang J. Pimozide suppresses colorectal cancer via Inhibition of Wnt\/\u03b2-catenin signaling pathway. Life Sci. 2018;209:267\u201373. https:\/\/doi.org\/10.1016\/j.lfs.2018.08.027.","journal-title":"Life Sci"},{"issue":"1","key":"562_CR54","first-page":"65","volume":"13","author":"EA Anil","year":"2002","unstructured":"Anil EA, Turgut TI, Rezaki M. Klozapin Tedavisini g\u00fc\u00e7lendirme: Bir G\u00f6zden ge\u00e7irme. Turk Psikiyatri Derg. 2002;13(1):65\u201377. G\u00d6\u011e\u00dc\u015e.","journal-title":"Turk Psikiyatri Derg"},{"issue":"3","key":"562_CR55","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1159\/000369751","volume":"35","author":"YC Yin","year":"2015","unstructured":"Yin YC, Lin CC, Chen TT, Chen JY, Tsai HJ, Wang CY, Chen SY. Clozapine induces autophagic cell death in non-small cell lung cancer cells. Cell Physiol Biochem. 2015;35(3):945\u201356. https:\/\/doi.org\/10.1159\/000369751.","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"562_CR56","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jdermsci.2013.07.012","volume":"72","author":"NA Massari","year":"2013","unstructured":"Massari NA, Medina VA, Cricco GP, Martinel Lamas DJ, Sambuco L, Pagotto R, Ventura C, Ciraolo PJ, Pignataro O, Bergoc RM, Rivera ES. Antitumor activity of Histamine and clozapine in a mouse experimental model of human melanoma. J Dermatol Sci. 2013;72(3):252\u201362. https:\/\/doi.org\/10.1016\/j.jdermsci.2013.07.012.","journal-title":"J Dermatol Sci"},{"issue":"7","key":"562_CR57","doi-asserted-by":"publisher","first-page":"e0132072","DOI":"10.1371\/journal.pone.0132072","volume":"10","author":"XN Shi","year":"2015","unstructured":"Shi XN, Li H, Yao H, Liu X, Li L, Leung KS, Kung HF, Lu D, Wong MH, Lin MC. In silico identification and in vitro and in vivo validation of anti-psychotic drug fluspirilene as a potential CDK2 inhibitor and a candidate anti-cancer drug. PloS One. 2015;10(7):e0132072. https:\/\/doi.org\/10.1371\/journal.pone.0132072.","journal-title":"PloS One"},{"issue":"67","key":"562_CR58","doi-asserted-by":"publisher","first-page":"111728","DOI":"10.18632\/oncotarget.22904","volume":"8","author":"Y Dong","year":"2017","unstructured":"Dong Y, Furuta T, Sabit H, Kitabayashi T, Jiapaer S, Kobayashi M, Ino Y, Todo T, Teng L, Hirao A, Zhao SG, Nakada M. Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug. Oncotarget. 2017;8(67):111728\u201341. https:\/\/doi.org\/10.18632\/oncotarget.22904.","journal-title":"Oncotarget"},{"issue":"2","key":"562_CR59","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10822-014-9811-6","volume":"29","author":"SP Patil","year":"2015","unstructured":"Patil SP, Pacitti MF, Gilroy KS, Ruggiero JC, Griffin JD, Butera JJ, Notarfrancesco JM, Tran S, Stoddart JW. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study. J Comput Aided Mol Des. 2015;29(2):155\u201363. https:\/\/doi.org\/10.1007\/s10822-014-9811-6.","journal-title":"J Comput Aided Mol Des"},{"issue":"2","key":"562_CR60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0014-2999(70)90043-9","volume":"11","author":"PA Janssen","year":"1970","unstructured":"Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, Van Nueten JM, Schaper WK. The Pharmacology of penfluridol (R 16341) a new potent and orally long-acting neuroleptic drug. Eur J Pharmacol. 1970;11(2):139\u201354.","journal-title":"Eur J Pharmacol"},{"issue":"20","key":"562_CR61","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.3390\/molecules24203659","volume":"24","author":"NM Tuan","year":"2019","unstructured":"Tuan NM, Lee CH. Penfluridol as a candidate of drug repurposing for anticancer agent. Molecules. 2019;24(20):3659. https:\/\/doi.org\/10.3390\/molecules24203659.","journal-title":"Molecules"},{"key":"562_CR62","doi-asserted-by":"publisher","first-page":"26165","DOI":"10.1038\/srep26165","volume":"6","author":"A Ranjan","year":"2016","unstructured":"Ranjan A, Srivastava SK. Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis. Sci Rep. 2016;6:26165. https:\/\/doi.org\/10.1038\/srep26165.","journal-title":"Sci Rep"},{"issue":"4","key":"562_CR63","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1158\/0008-5472.CAN-15-1233","volume":"76","author":"A Ranjan","year":"2016","unstructured":"Ranjan A, Gupta P, Srivastava SK. Penfluridol: an antipsychotic agent suppresses metastatic tumor growth in Triple-Negative breast Cancer by inhibiting integrin signaling Axis. Cancer Res. 2016;76(4):877\u201390. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1233.","journal-title":"Cancer Res"},{"key":"562_CR64","doi-asserted-by":"publisher","first-page":"109598","DOI":"10.1016\/j.biopha.2019.109598","volume":"121","author":"Q Xue","year":"2020","unstructured":"Xue Q, Liu Z, Feng Z, Xu Y, Zuo W, Wang Q, Gao T, Zeng J, Hu X, Jia F, Zhu Y, Xia Y, Yu L. Penfluridol: an antipsychotic agent suppresses lung cancer cell growth and metastasis by inducing G0\/G1 arrest and apoptosis. Biomed Pharmacother. 2020;121:109598. https:\/\/doi.org\/10.1016\/j.biopha.2019.109598.","journal-title":"Biomed Pharmacother"},{"key":"562_CR65","first-page":"219","volume":"23","author":"E Ayd\u0131n","year":"2010","unstructured":"Ayd\u0131n E, \u015eenormanc\u0131 \u00d6, Alt\u0131nba\u015f K, Kurt E. Leucopenia due to quetiapine abuse and combination with olanzapine: A case report. D\u00fc\u015f\u00fcnen Adam J Psychiatry Neurol Sci. 2010;23:219\u201322.","journal-title":"D\u00fc\u015f\u00fcnen Adam J Psychiatry Neurol Sci"},{"issue":"1","key":"562_CR66","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/tox.23380","volume":"37","author":"CM Su","year":"2022","unstructured":"Su CM, Lin SS, Wang HC, Hsu FT, Chung JG, Hsu LC. The inhibitory effect and mechanism of quetiapine on tumor progression in hepatocellular carcinoma in vivo. Environ Toxicol. 2022;37(1):92\u2013100. https:\/\/doi.org\/10.1002\/tox.23380.","journal-title":"Environ Toxicol"},{"issue":"23","key":"562_CR67","doi-asserted-by":"publisher","first-page":"37511","DOI":"10.18632\/oncotarget.16400","volume":"8","author":"Y Wang","year":"2017","unstructured":"Wang Y, Huang N, Li H, Liu S, Chen X, Yu S, Wu N, Bian XW, Shen HY, Li C, Xiao L. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma. Oncotarget. 2017;8(23):37511\u201324. https:\/\/doi.org\/10.18632\/oncotarget.16400.","journal-title":"Oncotarget"},{"key":"562_CR68","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3389\/fphar.2020.00596","volume":"11","author":"I Yunusa","year":"2020","unstructured":"Yunusa I, El Helou ML. The use of Risperidone in behavioral and psychological symptoms of dementia: A review of pharmacology, clinical evidence, regulatory approvals, and Off-Label use. Front Pharmacol. 2020;11:596. https:\/\/doi.org\/10.3389\/fphar.2020.00596.","journal-title":"Front Pharmacol"},{"issue":"6","key":"562_CR69","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.3390\/cancers12061560","volume":"12","author":"VC Chen","year":"2020","unstructured":"Chen VC, Hsieh YH, Lin TC, Lu ML, Liao YT, Yang YH, Hsu TC, Stewart R, Weng JC, Lee MJ, Chiu WC, Tzang BS. New use for old drugs: the protective effect of Risperidone on colorectal Cancer. Cancers (Basel). 2020;12(6):1560. https:\/\/doi.org\/10.3390\/cancers12061560.","journal-title":"Cancers (Basel)"},{"key":"562_CR70","doi-asserted-by":"publisher","first-page":"846455","DOI":"10.3389\/fphar.2022.846455","volume":"13","author":"VC Chen","year":"2022","unstructured":"Chen VC, Hsu TC, Lin CF, Huang JY, Chen YL, Tzang BS, McIntyre RS. Association of Risperidone with gastric cancer: triangulation method from cell study, animal study, and cohort study. Front Pharmacol. 2022;13:846455. https:\/\/doi.org\/10.3389\/fphar.2022.846455.","journal-title":"Front Pharmacol"},{"key":"562_CR71","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.4328\/ACAM.20724","volume":"12","author":"UD G\u00fcndo\u011fdu","year":"2021","unstructured":"G\u00fcndo\u011fdu UD, \u00c7oban F, Liman R, \u015eelli ME. Investigation of risperidone\u2019s anti-tumor activity on MCF-7 breast cancer cells. Ann Clin Anal Med. 2021;12:1267\u201371.","journal-title":"Ann Clin Anal Med"},{"issue":"6","key":"562_CR72","first-page":"CD009043","volume":"2016","author":"LE Hirsch","year":"2016","unstructured":"Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2016;2016(6):CD009043.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"562_CR73","doi-asserted-by":"publisher","first-page":"e00989","DOI":"10.1002\/prp2.989","volume":"10","author":"HJ Jeong","year":"2022","unstructured":"Jeong HJ, Jung CW, Kim HJ, Park B, Moon Y, Kim JY, Park MJ. Aripiprazole sensitizes head and neck cancer cells to ionizing radiation by enhancing the production of reactive oxygen species. Pharmacol Res Perspect. 2022;10(4):e00989. https:\/\/doi.org\/10.1002\/prp2.989.","journal-title":"Pharmacol Res Perspect"},{"issue":"10","key":"562_CR74","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.21873\/anticanres.11085","volume":"36","author":"S Suzuki","year":"2016","unstructured":"Suzuki S, Okada M, Kuramoto K, Takeda H, Sakaki H, Watarai H, Sanomachi T, Seino S, Yoshioka T, Kitanaka C. Aripiprazole, an antipsychotic and partial dopamine agonist, inhibits Cancer stem cells and reverses chemoresistance. Anticancer Res. 2016;36(10):5153\u201361. https:\/\/doi.org\/10.21873\/anticanres.11085.","journal-title":"Anticancer Res"},{"key":"562_CR75","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2147\/NDT.S36438","volume":"9","author":"L Alphs","year":"2013","unstructured":"Alphs L, Bossie CA, Sliwa JK, Fu DJ, Ma YW, Hulihan J. Paliperidone palmitate and Risperidone long-acting injectable in subjects with schizophrenia recently treated with oral Risperidone or other oral antipsychotics. Neuropsychiatr Dis Treat. 2013;9:341\u201350. https:\/\/doi.org\/10.2147\/NDT.S36438.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"17","key":"562_CR76","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.3390\/cancers13174357","volume":"13","author":"YS Liu","year":"2021","unstructured":"Liu YS, Huang BR, Lin CJ, Shen CK, Lai SW, Chen CW, Lin HJ, Lin CH, Hsieh YC, Lu DY. Paliperidone inhibits glioblastoma growth in mouse brain tumor model and reduces PD-L1 expression. Cancers (Basel). 2021;13(17):4357. https:\/\/doi.org\/10.3390\/cancers13174357.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"562_CR77","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1385\/JMN:22:3:189","volume":"22","author":"I Gil-Ad","year":"2004","unstructured":"Gil-Ad I, Shtaif B, Levkovitz Y, Dayag M, Zeldich E, Weizman A. Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors. J Mol Neuroscience: MN. 2004;22(3):189\u201398. https:\/\/doi.org\/10.1385\/JMN:22:3:189.","journal-title":"J Mol Neuroscience: MN"},{"key":"562_CR78","first-page":"1043","volume":"37","author":"S Tzadok","year":"2010","unstructured":"Tzadok S, Beery E, Israeli M, Uziel O, Lahav M, Fenig E, Nordenberg J. In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells. Int J Oncol. 2010;37:1043\u201351.","journal-title":"Int J Oncol"},{"key":"562_CR79","doi-asserted-by":"publisher","unstructured":"Chien W, Sun QY, Lee KL, Ding LW, Wuensche P, Torres-Fernandez LA,\u2026, Koeffler HP. Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Mol Oncol.\u00a02015;9:889-905. https:\/\/doi.org\/10.1016\/j.molonc.2015.01.002.","DOI":"10.1016\/j.molonc.2015.01.002"},{"issue":"14","key":"562_CR80","doi-asserted-by":"publisher","first-page":"7408","DOI":"10.3390\/ijms22147408","volume":"22","author":"D Duarte","year":"2021","unstructured":"Duarte D, Cardoso A, Vale N. Synergistic growth Inhibition of HT-29 Colon and MCF-7 breast Cancer cells with simultaneous and sequential combinations of antineoplastics and CNS drugs. Int J Mol Sci. 2021;22(14):7408. https:\/\/doi.org\/10.3390\/ijms22147408.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"562_CR81","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/biom12020190","volume":"12","author":"D Duarte","year":"2022","unstructured":"Duarte D, R\u00eama A, Amorim I, Vale N. Drug combinations: A new strategy to extend drug repurposing and Epithelial-Mesenchymal transition in breast and Colon cancer cells. Biomolecules. 2022;12(2):190. https:\/\/doi.org\/10.3390\/biom12020190.","journal-title":"Biomolecules"},{"key":"562_CR82","doi-asserted-by":"publisher","first-page":"101549","DOI":"10.1016\/j.tranon.2022.101549","volume":"26","author":"Y Wang","year":"2022","unstructured":"Wang Y, Xia L, Lin J, Gong L, Xia Y, Xu Y, Liu L, Bao J, Zhang C, Chai Y, Li H. Thioridazine combined with carboplatin results in synergistic Inhibition of triple negative breast cancer by targeting cancer stem cells. Translational Oncol. 2022;26:101549. https:\/\/doi.org\/10.1016\/j.tranon.2022.101549.","journal-title":"Translational Oncol"},{"key":"562_CR83","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.2147\/IJN.S104635","volume":"11","author":"X Jin","year":"2016","unstructured":"Jin X, Zou B, Luo L, Zhong C, Zhang P, Cheng H, Guo Y, Gou M. Codelivery of thioridazine and doxorubicin using nanoparticles for effective breast cancer therapy. Int J Nanomed. 2016;11:4545\u201352. https:\/\/doi.org\/10.2147\/IJN.S104635.","journal-title":"Int J Nanomed"},{"key":"562_CR84","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1016\/j.wneu.2019.04.180","volume":"128","author":"Z Liu","year":"2019","unstructured":"Liu Z, Jiang X, Gao L, Liu X, Li J, Huang X, Zeng T. Synergistic suppression of glioblastoma cell growth by combined application of Temozolomide and dopamine D2 receptor antagonists. World Neurosurg. 2019;128:e468\u201377. https:\/\/doi.org\/10.1016\/j.wneu.2019.04.180.","journal-title":"World Neurosurg"},{"issue":"9","key":"562_CR85","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/cancers11091310","volume":"11","author":"H Kim","year":"2019","unstructured":"Kim H, Chong K, Ryu BK, Park KJ, Yu MO, Lee J, Chung S, Choi S, Park MJ, Chung YG, Kang SH. Repurposing penfluridol in combination with Temozolomide for the treatment of glioblastoma. Cancers. 2019;11(9):1310. https:\/\/doi.org\/10.3390\/cancers11091310.","journal-title":"Cancers"},{"issue":"10","key":"562_CR86","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.3390\/cimb44100335","volume":"44","author":"D Duarte","year":"2022","unstructured":"Duarte D, Guerreiro I, Vale N. Novel strategies for Cancer combat: drug combination using repurposed drugs induces synergistic growth Inhibition of MCF-7 breast and HT-29 Colon Cancer cells. Curr Issues Mol Biol. 2022;44(10):4930\u201349. https:\/\/doi.org\/10.3390\/cimb44100335.","journal-title":"Curr Issues Mol Biol"},{"issue":"23\u201324","key":"562_CR87","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.bmcl.2018.10.036","volume":"28","author":"M Ashraf-Uz-Zaman","year":"2018","unstructured":"Ashraf-Uz-Zaman M, Sajib MS, Cucullo L, Mikelis CM, German NA. Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity. Bioorg Med Chem Lett. 2018;28(23\u201324):3652\u20137. https:\/\/doi.org\/10.1016\/j.bmcl.2018.10.036.","journal-title":"Bioorg Med Chem Lett"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-025-00562-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-025-00562-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-025-00562-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:05:35Z","timestamp":1762880735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-025-00562-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":87,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1007\/s40199-025-00562-1","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}